Charles River Laboratories Intl. Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? Charles River Laboratories Intl. Inc trades at $287.27 (market cap $13.46B), while VanEck Rare Earth/Strategic Metals trades at $77.24. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| CRL | REMX | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Sector/Thematic |
52-Week High | $282.00 | $109.53 |
52-Week Low | $145.57 | $56.60 |
Enterprise Value | $16.30B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.24, down 1.54% with a bullish technical signal supported by moving averages. The ETF provides exposure to 38 global rare earth companies amid growing U.S. efforts to secure critical mineral supply chains. Recent news highlights Energy Fuels' Utah plant expansion and ongoing geopolitical focus on reducing China's rare earth dominance.
Outlook remains tied to U.S. industrial policy and rare earth demand, though high volatility (~50% annualized) and China concentration pose risks. Investor sentiment is mixed, balancing strategic importance against execution challenges in building domestic supply chains.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →